Elamipretide

Drug Profile

Elamipretide

Alternative Names: Bendavia; ELA 4; MTP 131; Ocuvia; SBT-31; SPI-31; SS-31

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Stealth Peptides
  • Developer Stealth BioTherapeutics
  • Class Eye disorder therapies; Ischaemic heart disorder therapies; Oligopeptides; Peptides; Small molecules
  • Mechanism of Action Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Mitochondrial myopathies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute kidney injury; Corneal disorders; Heart failure; Leber's hereditary optic atrophy; Mitochondrial disorders; Reperfusion injury
  • Phase I/II Diabetic macular oedema; Dry age-related macular degeneration; Mitochondrial myopathies
  • Phase I Age-related macular degeneration
  • No development reported Chronic heart failure; Diabetes mellitus; Eye disorders; Neurodegenerative disorders

Most Recent Events

  • 28 Nov 2016 Stealth BioTherapeutics plans an extension phase II trial for Mitochondrial disorders (In adolescents, In adults) in USA (SC) (NCT02976038)
  • 18 Nov 2016 Efficacy data from the phase IIa EVOLVE trial in Acute kidney injury released by Stealth BioTherapeutics
  • 01 Oct 2016 Phase-I clinical trials in Age-related macular degeneration in USA (SC) (NCT02848313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top